非小细胞肺癌阿帕替尼联合化疗一线治疗与联合放化疗的疗效比较及对患者血清CEA及Cyfra21-1水平的影响  

Efficacy of Apatinib combined with First-line Chemotherapy and Radiotherapy and Chemotherapy in the Treatment of Non-small Cell Lung Cancer and its Effect on Serum CEA and Cyfra21-1 Levels

作　　者：李哲[1] 高敬华[1] 李永生[1] 赵瑾[1] 宋丽娜[1] 孙震 LI Zhe;GAO Jinghua;LI Yongsheng(Cangzhou Central Hospital,Cangzhou,061000)

机构地区：[1]河北省沧州市中心医院,061000

出　　处：《实用癌症杂志》2020年第5期732-734,744,共4页The Practical Journal of Cancer

摘　　要：目的探讨阿帕替尼联合化疗一线治疗及联合放化疗治疗非小细胞肺癌(NSCLC)的疗效及对患者血清CEA及Cyfra21-1水平的影响。方法将160例非小细胞肺癌患者遵循随机对照试验设计的原则分为实验组和对照组,每组80例,实验组接受阿帕替尼同期联合放、化疗,对照组接受阿帕替尼同期联合化疗。分别于治疗前及1个完整疗程后(不同个体间存在时间差异,以医嘱内容为准)进行生物采样,采用ELISA法测定受试者患者血清CEA及Cyfra21-1水平,采用SPSS16.0统计软件对数据进行处理。结果患者接受1个完整疗程后,实验组共发生转移3例,对照组共发生转移10例,转移率差异有统计学意义(χ^2=14.67,P=0.001)。治疗后实验组NSCLC患者血清CEA及Cyfra21-1水平均低于对照组,差异有统计学意义(P<0.001)。治疗后实验组及对照组中未发生转移的NSCLC患者血清CEA及Cyfra21-1水平均低于发生转移者,差异有统计学意义(P<0.001)。实验组、对照组、实验组及对照组治疗后未转移组、实验组治疗后转移组血清CEA及Cyfra21-1水平均呈统计学正相关(P均<0.05)。结论与阿帕替尼同期联合化疗相比,阿帕替尼同期联合放、化疗治疗非小细胞肺癌的疗效肯定,可更加显著地降低患者血清CEA及Cyfra21-1水平。Objective To investigate the efficacy of first-line treatment with apatinib combined with chemotherapy and chemoradiotherapy for non-small cell lung cancer and its effect on serum CEA and Cyfra21-1 levels.Methods 160 patients with NSCLC were enrolled.160 patients were divided into the experimental group and the control group according to the principle of randomized controlled trial design.Each group received 80 patients.The experimental group received apatinib combined with radiotherapy and chemotherapy,and the control group received apatinib combined with chemotherapy.Biosampling was performed before treatment and after a complete course of treatment(time difference between different individuals,subject to the contents of the doctor's advice).Serum CEA and Cyfra21-1 levels were determined by ELISA.SPSS16.0 statistical software was used.The data is processed.Results After receiving a complete course of treatment in this group of NSCLC patients,there were 3 cases of metastasis in the experimental group and 10 cases in the control group.The difference in metastasis rate was statistically significant(χ^2=14.67,P=0.001).The serum CEA and Cyfra21-1 levels in the experimental group were lower than those of the control group(P<0.001).The serum CEA and Cyfra21-1 levels were lower in the NSCLC patients who did not metastasize in the experimental group and the control group.The difference was statistically significant(P<0.001).The serum CEA and Cyfra21-1 levels in the experimental group,the control group,non metastasis group in the experimental group and the control group after treatment,and metastasis group in the experimental group after treatment were positively correlated(P<0.05).Conclusion The efficacy of apatinib combined with first-line chemotherapy and radiotherapy and chemotherapy combined with arbitratin and first-line chemotherapy without chemoradiotherapy for the treatment of non-small cell lung cancer can significantly reduce the serum CEA and Cyfra21-1 levels.

关 键 词：阿帕替尼 化疗 放疗 非小细胞肺癌 CEA CYFRA21-1 

分 类 号：R734.2[医药卫生—肿瘤]